New Parkinson's drug MF1 enters first human safety trial
Disease control
Recruiting now
This early-stage trial tests a new oral drug called MF1 in healthy adults and people with Parkinson's disease. The drug aims to block a harmful protein (alpha-synuclein) linked to Parkinson's. The main goal is to check safety and how the body processes the drug, not yet whether i…
Phase: PHASE1 • Sponsor: University of Shizuoka • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC